The global bone and mineral diagnostic testing market size reached USD 1.1 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 1.5 Billion by 2033, exhibiting a growth rate (CAGR) of 3.48% during 2025-2033. A considerable increase in the incidences of bone-related diseases, the escalating demand for early disease diagnosis and prevention, and continual technological advancements in the automation of assay represent some of the key factors driving the market.
Report Attribute
|
Key Statistics
|
---|---|
Base Year
|
2024
|
Forecast Years
|
2025-2033
|
Historical Years
|
2019-2024
|
Market Size in 2024
|
USD 1.1 Billion |
Market Forecast in 2033
|
USD 1.5 Billion |
Market Growth Rate 2025-2033 | 3.48% |
Bone and mineral diagnostic tests detect bone and mineral disorders that are performed using technologies, such as ELISA, CLIA, and RIA, to diagnose and assess treatment response. A bone and mineral metabolism disorder is a general term used to describe a range of conditions that can weaken bones due to mineral deficiencies like calcium, phosphorus, and vitamin D. In most cases, these tests are non-invasive, painless, and require minimal medication or administration, and several bone and mineral diagnostic tests are often performed using a combination method. The use of X-rays, computed tomography (CT) scans, or magnetic resonance imaging (MRI) can help identify or rule out fractures, wear and tear, and abnormal bone positions. Additionally, bone density tests (also known as bone densitometry or osteodensitometry) and bone scans (bone scintigraphy) detect the minerals in the bones, details on bone metabolism, and depict the different bone structures. Besides this, bone biopsies and bone marrow biopsies are also important forms of bone diagnostic testing, in which a thin needle is used to remove bone tissue to detect disease-related changes.
A considerable increase in the incidences of bone-related diseases on the global level is a significant factor driving the market. This can be attributed to the rising prevalence of sedentary lifestyle leading to deficiency of vitamin D. In line with this, the escalating demand for early disease diagnosis and prevention is also resulting in a higher uptake of various tests among the masses. Moreover, continual technological advancements in the automation of assay for enhanced diagnostic testing with lower turnaround times and increased accuracy in output are creating lucrative growth opportunities in the market. However, the augmenting costs of several bone diagnostic tests, limited reimbursements, along with limited detection capability are acting as significant factors that are restraining the market growth. On the contrary, the expansion of a wide range of point-of-care (POC) diagnostic tests and a considerable rise in public awareness toward preventive healthcare is creating a positive outlook for the market. The market is further driven by favorable initiatives undertaken by the government and non-profit organizations for promoting awareness about various diagnostic test procedures among the masses. Apart from this, the growing geriatric population that is more susceptible to developing these ailments is leading to the increasing incidences of bone disorders. Some of the other factors contributing to the market include rapid urbanization, rising medical expenditure, new product launches by the manufacturers, and extensive research and development (R&D) activities.
IMARC Group provides an analysis of the key trends in each segment of the global bone and mineral diagnostic testing market, along with forecasts at the global, regional, and country level from 2025-2033. Our report has categorized the market based on product, test type and application.
Product Insights
The report has provided a detailed breakup and analysis of the bone and mineral diagnostic testing market based on the product. This includes assays/consumables and instruments. According to the report, assays/consumables represented the largest segment.
Test Type Insights
The report has provided a detailed breakup and analysis of the bone and mineral diagnostic testing market based on the test type. This includes Enzyme-Linked Immunosorbent Assay (ELISA), Clinical Laboratory Improvement Amendments (CLIA), and others.
Application Insights
A detailed breakup and analysis of the bone and mineral diagnostic testing market based on the application has also been provided in the report. This includes vitamin D testing and bone metabolism. According to the report, vitamin D testing accounted for the largest market share.
Regional Insights
The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and Middle East and Africa. According to the report, North America was the largest market for bone and mineral diagnostic testing. Some of the factors driving the North America bone and mineral diagnostic testing market include the expanding geriatric population, rising healthcare expenditure, extensive research and development (R&D) activities conducted by key players, etc.
The report has also provided a comprehensive analysis of the competitive landscape in the global bone and mineral diagnostic testing market. Detailed profiles of all major companies have also been provided. Some of the companies covered include Abbott Laboratories, bioMérieux SA, DiaSorin S.p.A., Epitope Diagnostics Inc., F. Hoffmann-La Roche AG, QuidelOrtho Corporation, Siemens Healthineers AG (Siemens AG), etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Report Features | Details |
---|---|
Base Year of the Analysis | 2024 |
Historical Period | 2019-2024 |
Forecast Period | 2025-2033 |
Units | Billion USD |
Products Covered | Assays/Consumables, Instruments |
Test Types Covered | Enzyme-Linked Immunosorbent Assay (ELISA), Clinical Laboratory Improvement Amendments (CLIA), Others |
Applications Covered | Vitamin D Testing, Bone Metabolism |
Regions Covered | Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
Countries Covered | United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico |
Companies Covered | Abbott Laboratories, bioMérieux SA, DiaSorin S.p.A., Epitope Diagnostics Inc., F. Hoffmann-La Roche AG, QuidelOrtho Corporation, Siemens Healthineers AG (Siemens AG), etc. |
Customization Scope | 10% Free Customization |
Post-Sale Analyst Support | 10-12 Weeks |
Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |